IDStewardship

  • Home
  • Articles
  • LEARN ANTIBIOTICS
  • Study Guide
  • Resources
  • Q&A
  • #ASPchat
  • Contributors
  • About

Infectious Diseases Twitter Highlights: 1st Week July 2017

The “Infectious Diseases Twitter Highlights” column presents recent twitter posts that are of particular interest to the infectious diseases community and provides commentary.



Authored By: Mike Turk, Pharm.D., AAHIVP & Jamie Kisgen, Pharm.D., BCPS-AQ ID


Tweet #1

Article link is here

Commentary: An interesting, but short paper reviewing the 13 identified studies that compared serum to cerebral spinal fluid vancomycin concentrations. The ratios ranged from 0.00 to 0.81, and varied depending on the infection that was being treated. Regardless of this reported variability in concentrations, 83% of meningitis and 100% of ventriculitis patients achieved a cure.  No factor could predict the penetration rate of vancomycin into the CSF. An interesting data point (and one that tells us that even with variable penetration), is that the current dosing schemes used for CNS infections are working.

Tweet #2

Story is available here

Commentary: A new threat that has been percolating up from CDC reports – MDR Candida auris. Reports of 77 cases from New York, New Jersey, Illinois, Indiana, Maryland, Massachusetts, and Oklahoma have been filed with the CDC through May 2017. The article notes that subsequent screening of patients in the same wards found an additional 45 patients with colonization. 86% of isolates were resistant to fluconazole, and 43% to amphotericin B. In past research, the in-hospital mortality rate of a C. auris infection ranges from 30-60%. This is an emerging area of concern, and one to continue watching. Make sure your lab is up-to-date on the latest recommendations for testing and identification, which can be found here:

  • https://www.cdc.gov/fungal/diseases/candidiasis/recommendations.html

Tweet #3

Article is available here

Commentary: An excellent review of the data we have on cross-reactivity between penicillins and cephalosporins, and most importantly a good table that shows which ones have similar side chains to each other. This is an important resource for management of penicillin allergies, and while the article stresses we do not know the actual rate of cross-reactivity, a safe measure is to avoid agents with similar side chains. For me, the highlight of this article is the chart, and I will be putting it into my personal toolbox.

Tweet #4

Post is available here

Commentary: Infectious Diseases physician Dr. Paul Sax provides an excellent overview of the new fluoroquinolone delafloxacin (Baxdela), which was approved in June 2017 by the FDA for acute bacterial skin and skin structure infections (ABSSSI). He does a nice job outlining the key pros and cons of the drug and provides a little history on the class. Key pros include the spectrum of activity (MRSA and Pseudomonas!) and anionic properties, which may allow for increased accumulation in bacteria. Key cons/concerns include development of resistance and class adverse effects/warnings. As he points out, we do not need another skin drug at this time and its role in therapy may evolve over time as new indications are explored by the company or pioneering clinicians (e.g., CAP, SAB?, Osteomyelitis?, UTI?, Tb?).

Post #5

Article is here

Commentary: This is a systematic review of all human trials assessing the use of AMP+CTX in enterococcal endocarditis. It is relevant, because we see this combination quite often in practice. Four studies were identified, all observational – one was a comparison between ampicillin and gentamicin vs ampicillin and ceftriaxone, and the other three were simply ampicillin and ceftriaxone in combination. The studies were not well-powered, nor were they designed to show equivalence or non-inferiority; however in the comparison study, AMP+CTX was similar to AMP+gentamicin, and in all the studies AMP+CTX was well tolerated. The review concludes that this is a reasonable option for high-risk renal patients or those with aminoglycoside-resistant pathogens. A head to head randomized control study is needed though to truly determine which regimen should be first line. See blog post by Dr. David Paterson for more info and perspective: https://davidantibiotics.blogspot.com.au/2017/07/ampicillin-and-ceftriaxone-as-first.html


SUGGESTED FOR YOU:


 

LEARN ANTIBIOTICS

Paperback Book

Let’s Talk Micro

STEWARD PINS

Subscribe

Sign up for the monthly newsletter!

We will never spam you. We want you to like us. By clicking the Subscribe button, you accept the Terms of Service and Privacy Policy.

Categories

  • COVID-19
  • Healthcare At Large
  • Infectious Diseases & Antimicrobial Stewardship
  • Pharmacy News
  • Reality Check
  • Residency & Training
  • Facebook
  • Instagram
  • LinkedIn
  • Pinterest
  • Tumblr
  • Twitter
  • YouTube

Recent Posts

  • Pharmacy Student Study Strategies To Maximizing Learning In 2025 And Beyond
  • 5 Things To Know About Interpreting MRSA Nares Swab Results
  • Five Tidbits From The Largest International Meeting Of Clinical Microbiologists & Infectious Diseases Specialists In 2025
  • Five Things For Pharmacists To Know About Measles in 2025
  • 5 Things You Need To Know About The Learn Antibiotics Book Of Games

More Articles

Something Cool & Something Lame With 5 Antibiotics

Something Cool & Something Lame With 5 Antibiotics

5 Neat Things From The World Of Antimicrobials

5 Neat Things From The World Of Antimicrobials

5 Instances Of Challenging Antibiotic Workflows

5 Instances Of Challenging Antibiotic Workflows

Advice For New Pharmacy Interns: A White Coat Ceremony Key Note Speech

Advice For New Pharmacy Interns: A White Coat Ceremony Key Note Speech

Tags

antibiotic Antibiotics antimicrobial stewardship bcps beta-lactam cancer Chemotherapy Clinical Controversies clinical pharmacist clinical pharmacy community pharmacist Critical Care emergency medicine Emoji Game fellowship figure1 Hepatitis C hospital pharmacist hospital pharmacy Infectious Disease infectious diseases Lifestyle MRSA NAPLEX Natural Disaster oncology pharmacist one-on-one penicillin allergy PGY2 pharmacy fellowship Pharmacy Job pharmacy practice pharmacy residency pharmacy school pharmacy student Pharmacy technician PK-PD Compass Predatory Journals Rapid Diagnostic Testing residency social media student pharmacist study table transplant Zika

Recent

  • Pharmacy Student Study Strategies To Maximizing Learning In 2025 And Beyond
  • 5 Things To Know About Interpreting MRSA Nares Swab Results
  • Five Tidbits From The Largest International Meeting Of Clinical Microbiologists & Infectious Diseases Specialists In 2025
  • Five Things For Pharmacists To Know About Measles in 2025
  • 5 Things You Need To Know About The Learn Antibiotics Book Of Games

Search

Copyright 2016-2020 By Charlie Rose, LLC © · IDStewardship.com · Copyright · Privacy Policy · Terms · Contact